Newsletter

Subscribe and recieve updates on this company.

Text STOCKS to 72727 for mobile alerts

We are excited to present Alnylam Pharmaceuticals, Inc. (NASDAQ: ALNY).

Full DD Report for ALNY

You must become a subscriber to view this report.


Recent News from (NASDAQ: ALNY)

Alnylam Appoints Colleen Reitan to the Board of Directors
Alnylam Pharmaceuticals, Inc.  (Nasdaq: ALNY), the leading RNAi therapeutics company, announced today the appointment of a veteran healthcare leader, Colleen Reitan, to Alnylam’s Board of Directors, effective June 1, 2018. Ms. Reitan was the prior President of Plan Operations of...
Source: Business Wire
Date: May, 15 2018 07:00
Consolidated Research: 2018 Summary Expectations for STORE Capital, Microvision, International Game Technology, McKesson, Marinus Pharmaceuticals, and Alnylam Pharmaceuticals - Fundamental Analysis, Key Performance Indications
NEW YORK, May 11, 2018 (GLOBE NEWSWIRE) -- In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors, traders, and shareholders of STORE Capital Corporation (NYSE:STOR), Microvision, Inc. (NASDAQ:MVIS), In...
Source: GlobeNewswire
Date: May, 11 2018 08:25
Biotech Analysis Central Pharma News: Takeda's Acquisition Win, Ionis And Akcea Tumble, Alnylam's Advance In CNS
Welcome to Biotech Analysis Central Daily News, a daily news report and analysis about what has happened lately in the biotech industry. Takeda Acquires Shire For $62 Billion News: It was announced recently that Takeda ( TKPYY ) would pay $62 billion in total to acquire rare disea...
Source: SeekingAlpha
Date: May, 09 2018 01:40
Alnylam Reports Preclinical Data Demonstrating Central Nervous System (CNS) Delivery of RNAi Therapeutics
− Novel siRNA Conjugates Achieve Robust, Durable, and Broadly Distributed Silencing of CNS Gene Transcripts Following a Single Intrathecal Injection – − Company Expects First CNS-Targeted Development Candidate in 2018, First IND in Late 2019/Early 2020, and Capacit...
Source: Business Wire
Date: May, 08 2018 07:00
Alnylam Gets A Shortcut For Lumasiran... This News Is Highly Welcome
It was recently announced that Alnylam Pharmaceuticals ( ALNY ) was able to obtain a quicker path to approval for lumasiran. This will put the biotech ahead of schedule with approval of another one of its drugs in the pipeline possibly by 2020. That's because it is expecting a decision from ...
Source: SeekingAlpha
Date: May, 08 2018 00:53
Today's Research Reports on Trending Tickers: Sarepta Therapeutics and Alnylam Pharmaceuticals
NEW YORK, NY / ACCESSWIRE / May 7, 2018 / U.S. markets rallied on Friday, despite trade uncertainties and weak employment data, as a surge in Apple led to strong gains by the tech sector. The Dow Jones Industrial Average gained 1.39 percent to close at 24,262.51, while the S&P 500 Index...
Source: ACCESSWIRE IA
Date: May, 07 2018 08:20
Despite Recurrent Market Jitters, Alnylam Is Closing In On Multiple Drug Approvals
Holding shares in Alnylam Pharmaceuticals ( ALNY ) isn’t for the weak-hearted, as seen recently in reaction to a competitor’s unexpectedly strong clinical data. While Alnylam has long been volatile, and remains risky given the nature of the diseases it targets and its reliance ...
Source: SeekingAlpha
Date: May, 07 2018 08:00
Your Daily Pharma Scoop: Alnylam Update, Malinckrodt's Adcom Failure, Anika's Drug Recall
Analysis focus: ALNY Alnylam (ALNY), a leading RNAi therapeutics company, reported earnings last week. It beat on EPS, which at -$1.22 beat by $0.25. However, its revenue , despite rising 15% y/y, stood at $21.9mn, $8.25mn short of consensus. So, the company must have managed to cut costs...
Source: SeekingAlpha
Date: May, 07 2018 08:00
Blog Exposure - Alnylam Pharma Attained Alignment with FDA on Pivotal Study Design for Lumasiran for Treatment of Primary Hyperoxaluria Type 1
Stock Monitor: ACADIA Pharma Post Earnings Reporting LONDON, UK / ACCESSWIRE / May 07, 2018 / If you want access to our free research report on Alnylam Pharmaceuticals, Inc. (NASDAQ: ALNY ), all you need to do is sign up now by clicking the following link www.active-investors.com/reg...
Source: ACCESSWIRE IA
Date: May, 07 2018 07:20
3 Things In Biotech, May 4: Merck's New Combo, Alnylam Jump Starts, Ocata Gone Forever?
Note: Subscribers to Avisol Capital Partners Total Pharma Tracker got an early look at this publication. Try for free today and see what we're talking about! Here is some more information if you're curious . Welcome to another edition of "3 Things In Biotech," a daily digest dedicated...
Source: SeekingAlpha
Date: May, 05 2018 08:54

 


Last 5 Days Trading Activity

DateOpen PriceClose PriceHighLowVolume
2018-05-17101.33101.64102.42100.02865,688
2017-06-2078.9681.3884.181778.331,033,221
2017-06-1976.8079.0582.3176.451,306,879
2017-06-1675.8276.0776.2474.4851,264,505
2017-06-1574.3775.3575.7373.45833,774

Last 5 Days Short Activity

DateShort VolumeTotal VolumeShort PercentageShort Indicator
2018-08-13721,6781,386,64952.0447Short
2018-08-1066,573148,93944.6982Short
2018-08-09172,646481,27235.8729Short
2018-08-0866,439282,37923.5283Cover
2018-08-0791,793224,28240.9275Short

* Short Mode

Short Analysis provided by Squeeze Report. Get a complete short report on ALNY.


About Alnylam Pharmaceuticals, Inc. (NASDAQ: ALNY)

Logo for Alnylam Pharmaceuticals, Inc. (NASDAQ: ALNY)

Not available

 

Contact Information

 

 

Current Management

  • John M. Maraganore / President, CEO

Current Share Structure

  • Market Cap: $10,366,876,246 - 05/14/2018
  • Issue and Outstanding: 100,522,411 - 04/30/2018

 


Recent Filings from (NASDAQ: ALNY)

Report of unscheduled material events or corporate changes.
Filing Type: 8-KFiling Source: edgar
Filing Date: May, 15 2018
Amendment to the SC 13G filing
Filing Type: SC 13G/AFiling Source: edgar
Filing Date: May, 10 2018
Quarterly report with a continuing view of a company's financial position
Filing Type: 10-QFiling Source: edgar
Filing Date: May, 04 2018
Report of unscheduled material events or corporate changes.
Filing Type: 8-KFiling Source: edgar
Filing Date: May, 03 2018
Report of unscheduled material events or corporate changes.
Filing Type: 8-KFiling Source: edgar
Filing Date: April, 20 2018
Report of unscheduled material events or corporate changes.
Filing Type: 8-KFiling Source: edgar
Filing Date: April, 03 2018
Official notification to shareholders of matters to be brought to a vote (Proxy)
Filing Type: DEF 14AFiling Source: edgar
Filing Date: March, 23 2018
Report of unscheduled material events or corporate changes.
Filing Type: 8-KFiling Source: edgar
Filing Date: March, 14 2018
Annual report with a comprehensive overview of the company
Filing Type: 10-KFiling Source: edgar
Filing Date: February, 15 2018
Amendment to the SC 13G filing
Filing Type: SC 13G/AFiling Source: edgar
Filing Date: February, 14 2018

 

 


Daily Technical Chart for (NASDAQ: ALNY)

Daily Technical Chart for (NASDAQ: ALNY)


Stay tuned for daily updates and more on (NASDAQ: ALNY)

It most certainly could but even more important is the recent overwhelming interest in the company. Check out Investors Hub and search on Twitter

More to come on (NASDAQ: ALNY)

Do your DD and if you choose, be ready to go!


 

The Research: All source information contained in this email is from the public sources mentioned below.

 

 
 

Thank you

DD Report
@DDReports

 

 


Disclaimer: DD Report publishes reports providing information on selected companies. DD Report is not a registered investment advisor or broker-dealer. This report is provided as an information service only, and the statements and opinions in this report should not be construed as an offer or solicitation to buy or sell any security. DD Report accepts no liability for any loss arising from an investors reliance on or use of this report. An investment in ALNY is considered to be highly speculative and should not be considered unless a person can afford a complete loss of investment. DD Report has received up to $100,000 worth of crypto currency from a non-affiliated third party for the publication and circulation of this report. DD Report does not own any shares of ALNY and does not buy, sell, or trade any shares of ALNY. This report contains forward-looking statements, which involve risks, and uncertainties that may cause actual results to differ materially from those set forth in the forward-looking statements. Copyright 2018 by DD Report. All rights reserved. Our Full Disclaimer: http://dd.report/disclaimer/